Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Avmapki (avutometinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche, Verastem

Drug class:

MEK inhibitor, BRAF inhibitor, cRAF inhibitor

Related drugs:

‹

›

KRAS wild-type	Ovarian Cancer	KRAS wild-type	Ovarian Cancer	avutometinib + defactinib Sensitive: B - Late Trials avutometinib + defactinib Sensitive : B	avutometinib + defactinib Sensitive: B - Late Trials avutometinib + defactinib Sensitive : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
BRAF mutation	Ovarian Cancer	BRAF mutation	Ovarian Cancer	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2	avutometinib Sensitive: C2 – Inclusion Criteria avutometinib Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3	avutometinib + defactinib Sensitive: C3 – Early Trials avutometinib + defactinib Sensitive : C3
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3	avutometinib Sensitive: C3 – Early Trials avutometinib Sensitive : C3